

IRREGULAR PRODUCT

Anvisa suspends batch of generic Glucose 10%

Lot of injectable solution presented unsatisfactory laboratory results.

By: Ascom / Anvisa

Posted: 05/04/2017 00:05

Last Modified: 04/05/2017 00:23

Tweeter

 Compartilhar

Lot 74KF2612 of the drug Glucose 10% was suspended by Anvisa on Thursday (4/5). The suspension batch of injectable solution (<http://pesquisa.in.gov.br/imprensa/jsp/visualiza/index.jsp?data=04/05/2017&jornal=1&pagina=66&totalArquivos=112>), published in the Official Gazette (DOU), was prompted by unsatisfactory laboratory results.

According to the fiscal analysis report issued by the Central Public Health Laboratory of Bahia (Lacen-BA), the batch of the generic drug Glucose 10% presented foreign materials in the sample description test. The batch whose validity is 05/2018 has been suspended as far as distribution, commercialization and use.

The company Fresenius Kabi Brasil Ltda that manufactures the medicine is responsible for collecting all the stock of the lot in question.

Unregistered printers

Anvisa also suspended the advertising and clandestine trade of medical imaging diagnostic paper printers. The unregistered printers were manufactured by R10 Laser Comércio e Locações de Equipamentos para Informática Ltda.

The RE 1175/17 resolution suspending the distribution (<http://pesquisa.in.gov.br/imprensa/jsp/visualiza/index.jsp?data=04/05/2017&jornal=1&pagina=67&totalArquivos=112>), dissemination, marketing and use of the R10 Laser printers was published in the Official Gazette (DOU).

Read this and other health measures in full (<http://pesquisa.in.gov.br/imprensa/jsp/visualiza/index.jsp?data=04/05/2017&jornal=1&pagina=66&totalArquivos=112>).


Want to know Anvisa news first hand? Follow us on Twitter (@anvisa_oficial (http://twitter.com/anvisa_oficial))!


Did you find any problems in this news? Send an e-mail to noticias@anvisa.gov.br (<mailto:noticias@anvisa.gov.br>)


suspension (<http://portal.anvisa.gov.br/noticias?>

[p_p_id=101_INSTANCE_FXrpx9qY7FbU&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-2&p_p_col_count=1&p_r_p_564233524_tag=suspens%C3%A3o](http://portal.anvisa.gov.br/noticias?p_p_id=101_INSTANCE_FXrpx9qY7FbU&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-2&p_p_col_count=1&p_r_p_564233524_tag=suspens%C3%A3o)) irregular products ([p_p_id=101_INSTANCE_FXrpx9qY7FbU&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-2&p_p_col_count=1&p_r_p_564233524_tag=produtos+irregulares](http://portal.anvisa.gov.br/noticias?p_p_id=101_INSTANCE_FXrpx9qY7FbU&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-2&p_p_col_count=1&p_r_p_564233524_tag=produtos+irregulares)) medicine ([p_p_id=101_INSTANCE_FXrpx9qY7FbU&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-2&p_p_col_count=1&p_r_p_564233524_tag=medicamento](http://portal.anvisa.gov.br/noticias?p_p_id=101_INSTANCE_FXrpx9qY7FbU&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-2&p_p_col_count=1&p_r_p_564233524_tag=medicamento)) health product ([p_p_id=101_INSTANCE_FXrpx9qY7FbU&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-2&p_p_col_count=1&p_r_p_564233524_tag=produto+para+a+sa%C3%BAde](http://portal.anvisa.gov.br/noticias?p_p_id=101_INSTANCE_FXrpx9qY7FbU&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-2&p_p_col_count=1&p_r_p_564233524_tag=produto+para+a+sa%C3%BAde))

Back to the top!

 [\(https://www.facebook.com/AnvisaOficial/\)](https://www.facebook.com/AnvisaOficial/)

 [\(http://www.youtube.com/user/anvisaoficial\)](http://www.youtube.com/user/anvisaoficial)

 [\(https://twitter.com/anvisa_oficial\)](https://twitter.com/anvisa_oficial)

Barra GovBr (<http://www.acessoinformacao.gov.br/>) (<http://www.brasil.gov.br/>)

